How should I write a prescription for tirzepatide (Zepbound) for weight management for a female patient currently taking a little over 5 mg and transitioning from a compounded formulation to Eli Lilly’s direct program?

Prescribing Zepbound (Tirzepatide) for Weight Management

For a patient transitioning from compounded tirzepatide to Eli Lilly's Zepbound program at a dose slightly above 5 mg, prescribe Zepbound 7.5 mg subcutaneously once weekly, as this is the next FDA-approved dose in the titration schedule. 1, 2

Prescription Details

Write the prescription as follows:

• Medication: Zepbound (tirzepatide) 7.5 mg subcutaneous injection
• Dose: 7.5 mg subcutaneously once weekly
• Quantity: 4 auto-injector pens (for 4 weeks)
• Refills: As appropriate for ongoing therapy
• Instructions: Inject subcutaneously once weekly on the same day each week 1, 2

Rationale for 7.5 mg Dose Selection

• The FDA-approved titration schedule for Zepbound escalates by 2.5 mg increments every 4 weeks: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg weekly 2
• Since your patient is currently on "a little over 5 mg," the 7.5 mg dose represents the appropriate next step in the approved titration pathway 1, 2
• Never skip doses in the titration schedule—jumping from 5 mg directly to 10 mg markedly increases gastrointestinal adverse events and treatment discontinuation risk 1, 2

Critical Titration Rules

• Maintain each dose for a minimum of 4 weeks before advancing to the next increment 1, 2
• Accelerating titration faster than every 4 weeks is considered non-negotiable and substantially raises the risk of nausea, vomiting, and diarrhea 1, 2
• Advance to the next dose only when the current dose is well-tolerated and gastrointestinal symptoms have resolved or are only mild 2

Expected Weight Loss Outcomes by Maintenance Dose

• 7.5 mg weekly: Intermediate efficacy between 5 mg and 10 mg doses 1
• 10 mg weekly: Produces approximately 19.5% mean weight loss at 72 weeks, with 50% of patients achieving ≥20% loss 1, 3
• 15 mg weekly (maximum dose): Achieves 20.9–22.5% mean weight loss at 72 weeks, with 57% achieving ≥20% loss and nearly 40% losing ≥25% of body weight 1, 3

Ongoing Dose Escalation Plan

• After 4 weeks on 7.5 mg, if well-tolerated and additional weight loss is desired, advance to 10 mg weekly 1, 2
• After 4 weeks on 10 mg, if well-tolerated and additional weight loss is desired, advance to 12.5 mg weekly 2
• After 4 weeks on 12.5 mg, if well-tolerated and additional weight loss is desired, advance to the maximum dose of 15 mg weekly 1, 2
• FDA-approved maintenance doses are 5 mg, 10 mg, and 15 mg once weekly; 15 mg is the maximum allowable dose 1, 2

Common Pitfalls to Avoid

• Do not restart at 2.5 mg when transitioning from compounded tirzepatide to Zepbound if the patient has been on a stable dose and has not had a treatment interruption 2
• If therapy is interrupted for any duration, the patient must restart at 2.5 mg and repeat the full titration schedule to avoid severe gastrointestinal intolerance 1, 2
• Skipping the 2.5 mg starting dose (in treatment-naïve patients) increases the likelihood of clinically significant gastrointestinal side effects 1

Safety Monitoring

• Gastrointestinal effects (nausea, vomiting, diarrhea) occur in 25–35% of patients and are most frequent during dose escalation 1
• Advise patients to eat smaller meals, avoid high-fat foods, stop eating when feeling full, and maintain adequate hydration to mitigate symptoms 1
• Discontinue immediately if severe abdominal pain develops and evaluate for acute pancreatitis 1
• Monitor for gallbladder or biliary disease, especially during rapid weight loss in the first few months 1

Contraindications

• Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 1
• Pregnancy—discontinue before conception due to risk of early pregnancy loss and fetal abnormalities 1

Reproductive Considerations

• Tirzepatide markedly reduces oral contraceptive bioavailability 1
• Women of childbearing potential should use non-oral contraception (IUD, implant) or add a backup method for at least 4 weeks after each dose initiation or escalation 1